Clinical trial
A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma
NCT00065442 is registered in ClinicalTrials.gov with Dendreon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma
- Lead sponsor
- Dendreon
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2003
- Completion date
- January 31, 2009
- Enrollment
- 512 (actual)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer